The acute brain response to levodopa heralds dyskinesias in Parkinson disease

In Parkinson disease (PD), long‐term treatment with the dopamine precursor levodopa gradually induces involuntary “dyskinesia” movements. The neural mechanisms underlying the emergence of levodopa‐induced dyskinesias in vivo are still poorly understood. Here, we applied functional magnetic resonance imaging (fMRI) to map the emergence of peak‐of‐dose dyskinesias in patients with PD.

[1]  Kristoffer Hougaard Madsen,et al.  Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naive schizophrenia patients. , 2013, The international journal of neuropsychopharmacology.

[2]  P. Calabresi,et al.  Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap , 2010, The Lancet Neurology.

[3]  B. Biswal,et al.  Functional connectivity of human striatum: a resting state FMRI study. , 2008, Cerebral cortex.

[4]  S. Fahn.  How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both? , 2008, Annals of neurology.

[5]  Robert A. Hauser,et al.  Levodopa: Past, Present, and Future , 2008, European Neurology.

[6]  Mark W. Woolrich,et al.  Combined spatial and non-spatial prior for inference on MRI time-series , 2009, NeuroImage.

[7]  C Caltagirone,et al.  rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease , 2005, Neurology.

[8]  R. Passingham,et al.  Attention to Intention , 2004, Science.

[9]  Vesna Sossi,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover , 2001 .

[10]  A. Graybiel.  Habits, rituals, and the evaluative brain. , 2008, Annual review of neuroscience.

[11]  K. R. Ridderinkhof,et al.  Striatum and pre-SMA facilitate decision-making under time pressure , 2008, Proceedings of the National Academy of Sciences.

[12]  G. Kreiman,et al.  Internally Generated Preactivation of Single Neurons in Human Medial Frontal Cortex Predicts Volition , 2011, Neuron.

[13]  M. Cenci,et al.  Post‐ versus presynaptic plasticity in L‐DOPA‐induced dyskinesia , 2006, Journal of neurochemistry.

[14]  James B. Rowe,et al.  The medial frontal-prefrontal network for altered awareness and control of action in corticobasal syndrome , 2013, Brain : a journal of neurology.

[15]  Karl J. Friston,et al.  Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. , 2002, Brain : a journal of neurology.

[16]  A J Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study , 2001, Neurology.

[17]  Daniel K. Leventhal,et al.  Canceling actions involves a race between basal ganglia pathways , 2013, Nature Neuroscience.

[18]  G. Bartzokis,et al.  In vivo MR evaluation of age-related increases in brain iron. , 1994, AJNR. American journal of neuroradiology.

[19]  M Schulzer,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. , 2001, Annals of neurology.

[20]  F. Fadda,et al.  Role of striatal l‐DOPA in the production of dyskinesia in 6‐hydroxydopamine lesioned rats , 2006, Journal of neurochemistry.

[21]  D. Feinberg,et al.  Single‐shot 3D imaging techniques improve arterial spin labeling perfusion measurements , 2005, Magnetic resonance in medicine.

[22]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[23]  P. Bandettini,et al.  QUIPSS II with thin‐slice TI1 periodic saturation: A method for improving accuracy of quantitative perfusion imaging using pulsed arterial spin labeling , 1999, Magnetic resonance in medicine.

[24]  Corinna Cortes,et al.  Support-Vector Networks , 1995, Machine Learning.

[25]  R. Elliott,et al.  Playing it safe but losing anyway—Serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion , 2013, European Neuropsychopharmacology.

[26]  Karl J. Friston,et al.  Movement‐Related effects in fMRI time‐series , 1996, Magnetic resonance in medicine.

[27]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[28]  Yen F. Tai,et al.  Clinical correlates of levodopa-induced dopamine release in Parkinson disease , 2006, Neurology.

[29]  M Schulzer,et al.  PET demonstrates reduced dopamine transporter expression in PD with dyskinesias , 2009, Neurology.

[30]  U Sabatini,et al.  Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. , 1998, Brain : a journal of neurology.

[31]  N H Holford,et al.  The response to levodopa in parkinson's disease: Imposing pharmacological law and order , 1996, Annals of neurology.

[32]  K. Buck,et al.  Site-specific action of l-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic l-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats , 2010, Neuroscience.

[33]  S. Eickhoff,et al.  Functional neuroimaging of motor control in parkinson's disease: A meta‐analysis , 2014, Human brain mapping.

[34]  D J Brooks,et al.  Neuroimaging of dyskinesia. , 2000, Annals of neurology.

[35]  Roger A. Barker,et al.  Dynamic causal modelling of effective connectivity from fMRI: Are results reproducible and sensitive to Parkinson's disease and its treatment? , 2010, NeuroImage.

[36]  Thomas E. Nichols,et al.  Non-white noise in fMRI: Does modelling have an impact? , 2006, NeuroImage.

[37]  Anders Björklund,et al.  Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. , 2007, Brain : a journal of neurology.

[38]  S. Papapetropoulos.  Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap , 2011 .

[39]  G. E. Alexander,et al.  Parallel organization of functionally segregated circuits linking basal ganglia and cortex. , 1986, Annual review of neuroscience.

[40]  E. Bézard,et al.  Molecular mechanisms of l-DOPA-induced dyskinesia. , 2011, International review of neurobiology.

[41]  P. Cortelli,et al.  Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations. , 1990, Clinical neuropharmacology.

[42]  Viviana Versace,et al.  Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson’s disease , 2006, Clinical Neurophysiology.

[43]  Antonio Cerasa,et al.  Prefrontal alterations in Parkinson's disease with levodopa‐induced dyskinesia during fMRI motor task , 2012, Movement disorders : official journal of the Movement Disorder Society.

[44]  Vesna Sossi,et al.  Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. , 2004, Brain : a journal of neurology.